{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:21:30Z","timestamp":1787170890319,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s11096-016-0304-7","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:38:42Z","timestamp":1461717522000},"page":"880-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Resource use and cost of care with biologicals in Crohn\u2019s disease in South Africa: a retrospective analysis from a payer perspective"],"prefix":"10.1007","volume":"38","author":[{"given":"Jacqui","family":"Miot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niri","family":"Bhimsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,27]]},"reference":[{"issue":"9853","key":"304_CR1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"D Baumgart","year":"2012","unstructured":"Baumgart D, Sandborn W. Crohn\u2019s disease. Lancet. 2012;380(9853):1590\u2013605.","journal-title":"Lancet"},{"key":"304_CR2","unstructured":"NICE clinical guidance, 152. Crohn\u2019s disease: management in adults, young people and children. s.l.: NICE (National Institute for Health and Care Excellence); 2012. guidance.nice.org.uk\/cg152."},{"key":"304_CR3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","volume":"145","author":"J Terdiman","year":"2013","unstructured":"Terdiman J, Gruss C, Heidelbaugh J, Sultan S, Falck-Ytter Y, The AGA Institute Clinical Practice and Quality Management Committee. American Gasteroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF\u2014a biological drugs for the induction and maintenance of remission in inflammatory crohn\u2019s disease. Gasteroenterology. 2013;145:1459\u201363.","journal-title":"Gasteroenterology"},{"issue":"2","key":"304_CR4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1756283X14558193","volume":"8","author":"A Amiot","year":"2015","unstructured":"Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Ther Adv Gastroenterol. 2015;8(2):66\u201382.","journal-title":"Ther Adv Gastroenterol"},{"key":"304_CR5","unstructured":"NICE technology appraisal guidance, 187. Infliximab (review) and adalimumab for the treatment of Crohn\u2019s disease. NICE (National Institute of Health and Care Excellence); 2010. guidance.nice.org.uk\/ta187."},{"key":"304_CR6","unstructured":"SAGES Clinical Guideline Committee. SAGES clinical guidelines. Anti-tumour necrosis factor antibodies (Anti-TNF) in inflammatory bowel disease. SA Gastroenterol Rev. 2009;7(2):19\u201320."},{"key":"304_CR7","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/ibd.21488","volume":"17","author":"K Park","year":"2011","unstructured":"Park K, Bass D. Inflammatory bowel disease\u2014attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"304_CR8","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1097\/MIB.0b013e3182916046","volume":"19","author":"D Tang","year":"2013","unstructured":"Tang D, Harrington A, Lee J, Lin M, Armstrong E. A systematic review of economic studies on biological agents used to treat crohn\u2019s disease. Inflamm Bowel Dis. 2013;19(12):2673\u201394.","journal-title":"Inflamm Bowel Dis"},{"key":"304_CR9","doi-asserted-by":"crossref","unstructured":"Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn\u2019s disease. Health Technol Assess. 2011; 15(6):1\u2013244.","DOI":"10.3310\/hta15060"},{"key":"304_CR10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","volume":"63","author":"M Valk van der","year":"2014","unstructured":"van der Valk M, Mangen M-J, Leenders M, Dijkstra G, van Bodegraven A, Fidder H, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study. Gut. 2014;63:72\u20139.","journal-title":"Gut"},{"key":"304_CR11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ajg.2014.45","volume":"109","author":"M Vester-Andersen","year":"2014","unstructured":"Vester-Andersen M, Prosberg M, Jess T, Andersson M, Bengtsson B, Blixit T, et al. Disease course and surgery rates in inflammatory bowel disease: a population based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gasteroenterol. 2014;109:705\u201314.","journal-title":"Am J Gasteroenterol"},{"issue":"1","key":"304_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MIB.0000000000000250","volume":"21","author":"J Burisch","year":"2015","unstructured":"Burisch J, Vardi H, Pedersen N, Brinar M, Cukovic-Cavka S, Kaimakliotis I, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. Inflamm Bowel Dis. 2015;21(1):121\u201331.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"304_CR13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/gutjnl-2011-301397","volume":"61","author":"C Bernstein","year":"2012","unstructured":"Bernstein C, Loftus E Jr, Ng S, Lakatos P, Moum B. Epidemiology and natural history task force of the international organization for the study of inflammatory bowel disease (IOIBD). Hospitalisations and surgery in Crohn\u2019s disease. Gut. 2012;61(4):622\u20139.","journal-title":"Gut"},{"issue":"4","key":"304_CR14","first-page":"139","volume":"76","author":"E O\u2019Keefe","year":"1989","unstructured":"O\u2019Keefe E, Wright J, Froggatt J, Zabow D. Medium-term follow-up of Crohn\u2019s disease in Cape Town. S Afr Med J. 1989;76(4):139\u201341.","journal-title":"S Afr Med J"},{"issue":"8","key":"304_CR15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/BF02048362","volume":"36","author":"P Goldberg","year":"1993","unstructured":"Goldberg P, Wright J, Gerber M, Claassen R. Incidence of surgical resection for Crohn\u2019s disease. Dis Colon Rectum. 1993;36(8):736\u20139.","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"304_CR16","doi-asserted-by":"crossref","first-page":"e104859","DOI":"10.1371\/journal.pone.0104859","volume":"9","author":"A Basson","year":"2014","unstructured":"Basson A, Swart R, Jordaan E, Mazinu M, Watermeyer G. The association between race and Crohn\u2019s disease phenotype in the Western Cape population of South Africa, defined the by the Montreal classification system. PLoS One. 2014;9(8):e104859.","journal-title":"PLoS One"},{"key":"304_CR17","unstructured":"Annual Report Council for Medical Schemes\u00a02013\/14. South African council for medical schemes; 2014. www.medicalschemes.com . ISBN: 978-0-620-60270-9."},{"key":"304_CR18","unstructured":"Selected Historical Rates [Internet]. South African Reserve Bank [date unknown] [Cited 07 March 2016]. https:\/\/www.resbank.co.za\/research\/rates\/pages\/selectedhistoricalexchangeandinterestrates.aspx ."},{"issue":"9","key":"304_CR19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1155\/2011\/157604","volume":"25","author":"D Loomes","year":"2011","unstructured":"Loomes D, Teshima C, Jacobs P, Fedorack R. Health care resource use and costs for Crohn\u2019s disease before and after infliximab therapy. Can J Gastroenterol. 2011;25(9):497\u2013502.","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"304_CR20","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","volume":"128","author":"G Lichtenstein","year":"2005","unstructured":"Lichtenstein G, Yan S, Bala M, Blank M, Sands B. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn\u2019s disease. Gastroenterology. 2005;128(4):862\u20139.","journal-title":"Gastroenterology"},{"key":"304_CR21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/apt.12339","volume":"38","author":"J Lindsay","year":"2013","unstructured":"Lindsay J, Chipperfield R, Giles A, Wheeler C, Orchid T. On behalf of the INDIGO study investigators. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn\u2019s disease. Aliment Pharmacol Ther. 2013;38:52\u201361.","journal-title":"Aliment Pharmacol Ther"},{"key":"304_CR22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1365-2036.2010.04482.x","volume":"32","author":"M Sprakes","year":"2010","unstructured":"Sprakes M, Ford A, Suares N, Warren L, Greer D, Donnellan C, et al. Costs of care for Crohn\u2019s disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther. 2010;32:1357\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"304_CR23","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1038\/ajg.2010.139","volume":"105","author":"Z Nugent","year":"2010","unstructured":"Nugent Z, Blanchard J, Bernstein C. A population-based study of health-care resource use among infliximab users. Am J Gastoenterol. 2010;105:2009\u201316.","journal-title":"Am J Gastoenterol"},{"key":"304_CR24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/MEG.0b013e32836019b9","volume":"25","author":"M Sulz","year":"2013","unstructured":"Sulz M, Siebert U, Arvandi M, Gothe R, Wurm J, von Kanel R, et al. Predictors for hospitalisation and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study. Eur J Gasteroenterol Hepatol. 2013;25:790\u20137.","journal-title":"Eur J Gasteroenterol Hepatol"},{"issue":"10","key":"304_CR25","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/MCG.0b013e3181986917","volume":"43","author":"C Taxonera","year":"2009","unstructured":"Taxonera C, Rodgrigo L, Casellas F, Calvet X, Gomez-Camacho F, Ginard D, et al. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulising Crohn\u2019s disease. J Clin Gastroenterol. 2009;43(10):950\u20136.","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"304_CR26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s12325-011-0048-7","volume":"28","author":"C Carter","year":"2011","unstructured":"Carter C, Waters H, Smith D. Impact of infliximab adherence on Crohn\u2019s disease related healthcare utilisation and inpatient costs. Adv Ther. 2011;28(8):671\u201383.","journal-title":"Adv Ther"},{"issue":"10","key":"304_CR27","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s12325-009-0069-7","volume":"26","author":"S Kane","year":"2009","unstructured":"Kane S, Chao J, Mulani P. Adherence to infliximab maintenance therapy and healthcare utilisation and costs by Crohn\u2019s disease patients. Adv Ther. 2009;26(10):936\u201346.","journal-title":"Adv Ther"},{"key":"304_CR28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CEG.S41413","volume":"7","author":"R D\u2019Inca","year":"2014","unstructured":"D\u2019Inca R, Caccaro R. Measuring disease activity in Crohn\u2019s disease: what is currently available to the clinician. Clin Exp Gastroenterol. 2014;7:151\u201361.","journal-title":"Clin Exp Gastroenterol"},{"key":"304_CR29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.gastro.2014.08.003","volume":"148","author":"B Levesque","year":"2015","unstructured":"Levesque B, Sandborn W, Ruel J, Feagan B, Sands B, Colombel J-F. Converging goals of treatment of inflammatory bowel disease from clinical trials and practive. Gastroenterology. 2015;148:37\u201351.","journal-title":"Gastroenterology"},{"key":"304_CR30","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1365-2036.2007.03332.x","volume":"25","author":"D Epstein","year":"2007","unstructured":"Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn\u2019s disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther. 2007;25:1373\u201388.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"304_CR31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7196\/SAMJ.5609","volume":"102","author":"E Deetlefs","year":"2012","unstructured":"Deetlefs E, Epstein D, Watermeyer G, Seggie R, Thomson S. Tuberculosis in an inflammatory bowel disease cohort from South Africa. S Afr Med J. 2012;102(10):802\u20134.","journal-title":"S Afr Med J"},{"issue":"11","key":"304_CR32","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1002\/ibd.22873","volume":"18","author":"D Sussman","year":"2012","unstructured":"Sussman D, Kubiliun N, Mulani P, Chao J, Gillis C, Yang M, et al. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis. 2012;18(11):2043\u201355.","journal-title":"Inflamm Bowel Dis"},{"key":"304_CR33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CEOR.S66338","volume":"6","author":"L Esposti","year":"2014","unstructured":"Esposti L, Sangiorgi D, Perrone V, Radice S, Clementi E, Perone F, et al. Adherence and resource use among patients treated with biological drugs: findings from BEETLE Study. Clinicoeco Outcomes Res. 2014;6:401\u20137.","journal-title":"Clinicoeco Outcomes Res"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-016-0304-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-016-0304-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-016-0304-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T01:54:55Z","timestamp":1559354095000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-016-0304-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,27]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1007\/s11096-016-0304-7","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,27]]}}}